Trial Profile
A Placebo-Controlled Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Acronyms APEX-PD
- Sponsors IMPAX Laboratories
- 25 Nov 2015 According to Impax Laboratories' media release, the European Commission has granted marketing approval for levodopa/carbidopa modified release combination (NUMIENT) for the symptomatic treatment of adult patients with Parkinson's disease.
- 25 Sep 2015 According to Impax Laboratories' media release, the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending levodopa/carbidopa modified release combination (NUMIENT) for the symptomatic treatment of adult patients with Parkinson's disease.
- 25 Apr 2015 Results comparing efficacy from APEX-PD, ADVANCE-PD and ASCEND-PD trials presented at the 67th Annual Meeting of the American Academy of Neurology.